Clinical trial · no report yet · Phase 3
INAVO 123
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- NCT06790693 ↗
- Recruiting
- Hoffmann-La Roche
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 7 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Cancer
- Interventions
- Inavolisib; Placebo; CDK4/6i; Letrozole
- Arms
- Inavolisib + Letrozole + CDK4/6i · Experimental
- Placebo + Letrozole + CDK4/6i · Placebo comparator
- Enrollment
- 450 (estimated)
- Primary outcomes
- Progression-Free Survival (PFS)
- Sponsor
- Hoffmann-La Roche
- Start
- Apr 9, 2025
- Primary completion
- Jan 31, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT06790693 · updated Oct 6, 2026